Related Experiment Video

Updated: Feb 3, 2026

In Silico Clinical Trials for Cardiovascular Disease
09:09

In Silico Clinical Trials for Cardiovascular Disease

Published on: May 27, 2022

2.3K

Oral antiplatelet agents in cardiovascular disease

Joseph Pultar1,2, Patricia P Wadowski1,2, Simon Panzer3

  • 11 Department of Internal Medicine II, Medical University of Vienna, Vienna, Austria.

VASA. Zeitschrift Fur Gefasskrankheiten
|October 17, 2018
PubMed

Insights

Aspirin and newer antiplatelet agents like prasugrel and ticagrelor are crucial for preventing cardiovascular events. This review covers oral antiplatelet therapies for conditions including acute coronary syndromes and peripheral artery disease.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Antiplatelet agents are essential in managing ischemic heart disease, cerebrovascular disease, and peripheral artery disease (PAD).
  • Aspirin is a cornerstone for secondary prevention of atherothrombotic events in cardiovascular disease.
  • Dual antiplatelet therapy (DAPT) with aspirin and an adenosine diphosphate (ADP) receptor antagonist is standard for acute coronary syndromes (ACS) and angioplasty with stent implantation.

Purpose of the Study:

  • To review current evidence on oral antiplatelet agents in cardiovascular disease.
  • To highlight the role of aspirin, clopidogrel, prasugrel, ticagrelor, and vorapaxar.

Main Methods:

  • This is a review article.
  • It summarizes existing clinical evidence and guideline recommendations.

Main Results:

  • Newer ADP P2Y12 inhibitors (prasugrel, ticagrelor) offer improved outcomes in ACS compared to clopidogrel.
  • Vorapaxar provides an additional mechanism by inhibiting thrombin-induced platelet activation, approved for PAD and post-myocardial infarction patients.

Conclusions:

  • Oral antiplatelet agents are vital in reducing mortality and morbidity in cardiovascular diseases.
  • The landscape of antiplatelet therapy continues to evolve with newer agents offering enhanced efficacy.

More Related Videos

Author Spotlight: Establishing an Accurate Microhardness Testing Protocol for Craniofacial Tissues06:16

Author Spotlight: Establishing an Accurate Microhardness Testing Protocol for Craniofacial Tissues

Published on: April 26, 2024

1.3K
Digital PCR for Quantifying Circulating MicroRNAs in Acute Myocardial Infarction and Cardiovascular Disease04:41

Digital PCR for Quantifying Circulating MicroRNAs in Acute Myocardial Infarction and Cardiovascular Disease

Published on: July 3, 2018

8.7K

Related Concept Videos

Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
664
Oral Hypoglycemic Agents: Sulfonylureas01:17

Oral Hypoglycemic Agents: Sulfonylureas

Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide...
1.1K
Psychoneuroimmunology: Cardiovascular Disease01:27

Psychoneuroimmunology: Cardiovascular Disease

Psychoneuroimmunology (PNI) is a multidisciplinary field that examines how psychological factors, particularly stress, interact with the immune system and impact physical health. Research in PNI has shown that chronic or traumatic stress can disrupt both the hypothalamic-pituitary-adrenal axis and the sympathetic nervous system. These disruptions contribute to serious health conditions, including cardiovascular diseases.
A key area of focus in PNI is the relationship between stress and coronary...
573
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
671
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
576
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
538